Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, ...
Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically significant and clinically meaningful reduction in the ...
ProModRx adds infrastructure and capabilities that strengthen D2’s support from initial access through ongoing patient servicesSaint Charles, Mo., April 16, 2026 – D2 Solutions, a healthcare ...
TauRx today announced results from a confirmatory study evaluating hydromethylthionine mesylate in participants with mild cognitive impairment and mild to moderate dementia due to Alzheimer’s disease ...
New controlled cleaning and sterilization service supports biopharma customers with ready-to-use single-use assembliesKAISERSLAUTERN, Germany, April 20, 2026 / Biotech Newswire / -- Freudenberg ...
Strategic acquisition marks the first step in Panthera’s European expansion, strengthening its global competitiveness Panthera Biopartners (Panthera), the leading UK based clinical trial Site ...
Speech could be a key clinical marker in neurodegenerative disease drug trials, says leading biotech
SynaptixBio, the only company licensed to commercialise a treatment for the rare, deadly disease H-ABC, says families value the ability to communicate more than other disease impactsSpeech is rapidly ...
Real-world evidence is increasingly demonstrating tobacco harm reduction (THR) in action, so why do many public health bodies and regulators remain sceptical? Joe Thompson, Group Science & Regulatory ...
A study led by Karl Landsteiner University shows that the disease affects whole-brain communication networks, and that this may help predict survival.Krems, Austria, 21 April 2026 – Glioblastoma, the ...
Study of CAL101, which targets a novel upstream pathway implicated in fibrotic disease, enrolls 161 patients more than six months ahead of plan; topline data expected Q1 2027Drug candidate, a ...
Ondine Biomedical Inc. (LON: OBI), a leader in photodisinfection-based therapies, is pleased to announce that two of its abstracts have been accepted for poster presentation at the upcoming World ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results